Hemolytic Anemias- Part 7: Paroxysmal nocturnal hemoglobinuria (PNH)
18.7 هزار بار بازدید -
2 سال پیش
-
#ilovepathology
#ilovepathology #hemolyticanemia #pathology #medicalschoolpathology #pathology
Definition: Paroxysmal nocturnal hemoglobinuria (PNH) is a disease that results from acquired mutations in the phosphatidylinositol glycan complementation group A gene (PIGA), an enzyme that is essential for the synthesis of certain membrane-associated complement regulatory protein
Typical Clinical Triad: Intravascular hemolysis, Bone marrow failure, and propensity to Thromboembolism
History and Epidemiology: first described in the 18th century. It is a rare disease, with a worldwide prevalence estimated in the range of 1–5 cases per million regardless of ethnicity; an increased prevalence is reported in some regions which also harbor higher incidence of aplastic anemia (eg, Thailand and some other Asian countries)
Unique feature: only hemolytic anemia caused by an acquired genetic defect
Pathophysiology:
Somatic mutation in the Phosphatidylinositol glycan complement group A gene(PIGA gene)
[Cause: PIGA is X-linked and subject to lyonization (random inactivation of one X chromosome in cells of females) leading to a single acquired mutation in the active PIGA gene of any given cell]
↓
Deficient specialized phospholipid called glycosylphosphatidylinositol (GPI) linked protein in a hematopoetic stem cell
PNH blood cells are deficient in three GPI-linked proteins that regulate complement activity:
(1) Decay-accelerating factor or CD55
(2) Membrane inhibitor of reactive lysis or CD59
Definition: Paroxysmal nocturnal hemoglobinuria (PNH) is a disease that results from acquired mutations in the phosphatidylinositol glycan complementation group A gene (PIGA), an enzyme that is essential for the synthesis of certain membrane-associated complement regulatory protein
Typical Clinical Triad: Intravascular hemolysis, Bone marrow failure, and propensity to Thromboembolism
History and Epidemiology: first described in the 18th century. It is a rare disease, with a worldwide prevalence estimated in the range of 1–5 cases per million regardless of ethnicity; an increased prevalence is reported in some regions which also harbor higher incidence of aplastic anemia (eg, Thailand and some other Asian countries)
Unique feature: only hemolytic anemia caused by an acquired genetic defect
Pathophysiology:
Somatic mutation in the Phosphatidylinositol glycan complement group A gene(PIGA gene)
[Cause: PIGA is X-linked and subject to lyonization (random inactivation of one X chromosome in cells of females) leading to a single acquired mutation in the active PIGA gene of any given cell]
↓
Deficient specialized phospholipid called glycosylphosphatidylinositol (GPI) linked protein in a hematopoetic stem cell
PNH blood cells are deficient in three GPI-linked proteins that regulate complement activity:
(1) Decay-accelerating factor or CD55
(2) Membrane inhibitor of reactive lysis or CD59
2 سال پیش
در تاریخ 1401/07/09 منتشر شده
است.
18,775
بـار بازدید شده